NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) shares fell 7% during mid-day trading on Wednesday . The stock traded as low as $10.30 and last traded at $10.12. 296,896 shares traded hands during trading, a decline of 62% from the average session volume of 788,880 shares. The stock had previously closed at $10.88.
Analysts Set New Price Targets
Several research firms recently weighed in on NEO. Bank of America reduced their price objective on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 19th. Benchmark lowered NeoGenomics from a "buy" rating to a "hold" rating in a research note on Monday, January 13th. Needham & Company LLC reduced their price objective on NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, February 19th. Piper Sandler reduced their price objective on NeoGenomics from $21.00 to $18.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Finally, Jefferies Financial Group began coverage on NeoGenomics in a research note on Tuesday, December 10th. They issued a "buy" rating and a $22.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $19.60.
Check Out Our Latest Stock Analysis on NEO
NeoGenomics Stock Up 3.2 %
The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The company has a market capitalization of $1.26 billion, a P/E ratio of -15.84 and a beta of 1.28. The stock has a 50-day moving average price of $13.11 and a 200-day moving average price of $14.80.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The company had revenue of $172.00 million for the quarter, compared to the consensus estimate of $173.40 million. On average, research analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.
Institutional Investors Weigh In On NeoGenomics
Several large investors have recently added to or reduced their stakes in NEO. KBC Group NV grew its stake in NeoGenomics by 33.1% during the third quarter. KBC Group NV now owns 4,530 shares of the medical research company's stock worth $67,000 after purchasing an additional 1,127 shares during the period. Royce & Associates LP grew its stake in NeoGenomics by 3.2% during the third quarter. Royce & Associates LP now owns 639,476 shares of the medical research company's stock worth $9,432,000 after purchasing an additional 19,780 shares during the period. Natixis Advisors LLC grew its stake in NeoGenomics by 54.1% during the third quarter. Natixis Advisors LLC now owns 33,982 shares of the medical research company's stock worth $501,000 after purchasing an additional 11,936 shares during the period. Segall Bryant & Hamill LLC grew its stake in NeoGenomics by 67.0% during the third quarter. Segall Bryant & Hamill LLC now owns 1,893,407 shares of the medical research company's stock worth $27,928,000 after purchasing an additional 759,524 shares during the period. Finally, Jennison Associates LLC grew its stake in NeoGenomics by 4.7% during the third quarter. Jennison Associates LLC now owns 1,276,468 shares of the medical research company's stock worth $18,828,000 after purchasing an additional 57,041 shares during the period. Institutional investors and hedge funds own 98.50% of the company's stock.
NeoGenomics Company Profile
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Featured Articles
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
